Updated Clinical efficacy and safety of MK-3475 (Anti-PD-1 monoclonal antibody) in advanced melanoma

¹Institut Gustave-Roussy, Villejuif, France; ²The Angeles Clinic and Research Institute, Los Angeles, CA, USA; ³University of California, Los Angeles, CA, USA; ⁴Dana-Farber Cancer Institute, Boston, MA, USA; ⁵MD Anderson Cancer Center, Houston, TX, USA; ⁶Westmead Hospital and Melanoma Institute Australia, Sydney, NSW, Australia; ⁷Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ⁸Calvary Mater Newcastle Hospital, Newcastle, NSW, Australia; ⁹H. Lee Moffitt Cancer Center, Tampa, FL, USA; ¹⁰Mayo Clinic, Jacksonville, FL, USA; ¹¹Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA; ¹²Mayo Clinic, Rochester, MN, USA; ¹³South Texas Accelerated Research Therapeutics, San Antonio, TX, USA; ¹⁴University of Pittsburgh, Pittsburgh, PA, USA; ¹⁵Princess Margaret Hospital, Toronto, ON, Canada; ¹⁶Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; ¹⁷University of California, San Francisco, CA, USA